CHF117.9m market cap
CHF0.15 last close
Evolva is a Swiss, high-tech fermentation company. It has a proprietary yeast technology platform, which it uses to create and manufacture high-value speciality molecules for nutritional and consumer products.
Investment summary
Nootkatone US EPA approval in pest control is delayed as the EPA seeks clarification on one study. Evolva is collaborating with the EPA on the matter. The first EverSweet royalty – albeit small – was received in Q418, Evolva’s overall geographical and product footprint continues to expand, and the pipeline remains robust. The company’s aim is to reach cash break-even by FY21/23. H119 results are due on 21 August.
Y/E Dec |
Revenue (CHFm) |
EBITDA (CHFm) |
PBT (CHFm) |
EPS (CHFc) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 6.8 | (37.6) | (40.9) | (7.0) | N/A | N/A |
| 2018A | 8.9 | (23.4) | (25.4) | (3.0) | N/A | N/A |
| 2019E | 11.5 | (14.5) | (15.2) | (1.6) | N/A | N/A |
| 2020E | 18.8 | (9.4) | (9.9) | (1.0) | N/A | N/A |
| Last updated on 15/08/2019 | ||||||
Industry outlook
Food and health ingredients continue to be in the sweet spot as consumers demand healthier products with cleaner labels without compromising on taste or convenience. Evolva’s fermentation platform aims to deliver these benefits while reducing production costs.
Last updated on 15/08/2019
Sector |
|---|
| Consumer |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (CHFm) | 34.9 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Gerard Hoetmer | Chairman |
| Oliver Walker | CEO |
